

Prognostic value of QRS duration and ejection fraction: going back to the roots

Commentary on

Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration

Hoang M. Lai, Wilbert S. Aronow, Archana Rachdev, Amit Asija, Khanh V. Lai, Jerry George, John A. McClung

Arch Med Sci 2008; 4, 2: 140–142

Leonardo De Luca¹, John Parissis², Gerasimos S. Filippatos²

¹Department of Cardiovascular Sciences, Division of Cardiology, Laboratory of Interventional Cardiology, European Hospital, Rome, Italy

²Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece

Submitted: 24 May 2008

Accepted: 10 June 2008

Arch Med Sci 2008; 4, 2: 143–144
Copyright © 2008 Termedia & Banach

Corresponding author:

Gerasimos S. Filippatos, MD
Department of Cardiology
Heart Failure Unit
Athens University Hospital
Attikon
28 Douk. Plakentias Street
11523 Athens, Greece
Phone: +30 210 5832195
E-mail: geros@otenet.gr

Recent developments in cardiac imaging and biological markers have attracted intense interest within the cardiology community. Improvements in speed of measurement, image quality, reliability, and range of applications have evolved to the point where costly cardiac imaging and new biomarkers are increasingly seen as clinical tools on a daily basis. Nevertheless, simple and widely available parameters such as QRS duration and left ventricular (LV) dimensions and ejection fraction (EF) have been shown to be among the most powerful predictors of survival after acute myocardial infarction [1, 2], in chronic heart failure (HF) [3-5] and among people free of overt cardiovascular disease [6, 7].

Left or right bundle branch block occurs in up to 47% of HF patients and left is more common than right bundle branch block. Patients with HF and QRS prolongation have higher all-cause mortality and possibly a higher incidence of sudden cardiac death than those with narrow QRS complexes [8, 9]. Notably, in patients with HF, an inverse correlation exists between QRS prolongation and LVEF [10, 11]. In a study of nearly 3,500 patients with HF, Shenkman et al. [12] found a stepwise increase in the prevalence of systolic LV dysfunction as QRS complex duration increased progressively above 120 ms. Another study, conducted in 343 patients with HF, reported LVEF of 41, 36, 29, and 25% in patients with QRS durations of ≤ 100 , 100 to 119, 120 to 149, and ≥ 150 ms, respectively [10]. These observations in patients with HF are in keeping with the findings of Murkofsky et al. [13], who analyzed 226 patients (without typical bundle branch block, pacemaker, or stated HF) referred for radionuclide exercise ventriculography. The study indicated a high likelihood of an abnormal LVEF $\leq 45\%$ with a QRS ≥ 0.10 s. Although sensitivity was not very high, specificity rose for each 0.01-s increase in QRS duration so that it reached 99% with a QRS increment from 0.10 to 0.12 s [13].

In this issue of the *Journal* Lai et al. [14] evaluated the relationship between abnormal QRS duration (≥ 120 s) on the resting ECG and LVEF ($< 50\%$) by 2-dimensional echocardiography and long-term mortality among 1,040 patients with coronary heart disease or hypertensive heart disease with left ventricular hypertrophy. At a mean follow-up of 17 ± 10 months the authors demonstrated an increased risk for all-cause mortality among patients with abnormal LVEF or abnormal QRS duration, or both. This is the first study that has found a consistent proportionality between two surrogate endpoints, such as abnormal EF and QRS duration, and the subsequent change in long-term mortality among patients at high risk for cardiovascular events.

In accordance with these data, Silverman et al. [8] reported that QRS prolongation had a different prognostic value in patients with chronic HF with non-ischaemic vs. ischaemic cardiomyopathy. They found that a prolonged QRS carried a significantly worse prognosis only in patients with non-ischaemic cardiomyopathy. These results are at variance with the observations of Iuliano et al. [15], who found no significant difference (median follow-up, 45 months) in mortality or sudden death in patients with non-ischaemic cardiomyopathy and $QRS \geq 0.12$ vs. $QRS < 0.12$ s. However, Iuliano et al. [15] reported a significantly higher all-cause and sudden-death mortality rate in patients with ischaemic cardiomyopathy and a longer QRS duration. Comparing the groups with $QRS \geq 0.12$ vs. $QRS < 0.12$ s (median follow-up, 45 months), the mortality was 51 vs. 34% and the sudden death rate was 25 vs. 17%, respectively [15].

Therefore, the findings of Lai et al. confirm that QRS duration and LVEF might have important clinical implications for assessing long-term prognosis and consequent management in patients at risk. In addition, they suggest once more that simple diagnostic tools such as ECG and 2-D echocardiography may provide rapid, reliable, and cost-effective information for identifying patients at higher risk for subsequent cardiovascular events in daily practice.

References

1. Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after myocardial infarction. *Circulation* 1987; 75: 93-7.
2. Bauer A, Watanabe MA, Barthel P, Schneider R, Ulm K, Schmidt G. QRS duration and late mortality in unselected post-infarction patients of the revascularization era. *Eur Heart J* 2006; 27: 427-33.
3. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. *J Am Coll Cardiol* 2005; 46: 2183-92.
4. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. *Am J Cardiol* 1993; 72: 672-6.
5. Wong M, Johnson G, Shabetai R, et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. *Circulation* 1993; 87: 65-70.
6. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Aakhus T. Heart volume and cardiovascular mortality. A 16-year follow-up study of 1984 healthy middle-aged men. *Eur Heart J* 1993; 14: 592-6.
7. Gonzalez MM, Berg RA, Nadkarni VM, et al. Left ventricular systolic function and outcome after in-hospital cardiac arrest. *Circulation* 2008; 117: 1864-72.
8. Silverman ME, Pressel MD, Brackett JC, Lauria SS, Gold MR, Gottlieb SS. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. *Am J Cardiol* 1995; 75: 460-4.
9. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. *Circulation* 2003; 107: 1764-9.
10. Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. *Am J Cardiol* 2004; 93: 244-6.
11. Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. *Heart* 2003; 89: 54-60.
12. Shenkman HJ, Pampati V, Khandelwal AK, et al. Congestive heart failure and QRS duration: establishing prognosis study. *Chest* 2002; 122: 528-34.
13. Murkofsky RL, Dangas G, Diamond JA, Mehta D, Schaffer A, Ambrose JA. A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction. *J Am Coll Cardiol* 1998; 32: 476-82.
14. Lai HM, Aronow WS, Rachdev A, Asija A, Lai KV, George J, McClung JA. Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration. *Arch Med Sci* 2008; 4: 140-2.
15. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN; Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. *Am Heart J* 2002; 143: 1085-91.